Cellid Co., Ltd.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2006 and listed on KOSDAQ in 2019, Cellid is a biopharmaceutical company specializing in cancer immunotherapy vaccines and infectious disease preventive vaccines. Using its proprietary platforms CeliVax (cancer immunotherapy vaccine) and Ad5/35 (adenovirus vector preventive vaccine), it holds a pipeline including BVAC-C, BVAC-E6E7 for head and neck cancer (Phase 1/2a approved November 2024), the COVID-19 vaccine AdCLD-CoV19-1, the Omicron-targeting AdCLD-CoV19-1 OMI (Phase 3 ongoing), and the variant-targeting AdCLD-CoV19-1 LP.8.1. It completed a GMP center in November 2020 and signed its first CMO/CDMO contract manufacturing agreement in September 2022; its R&D spending over the last three years was KRW 12.0 billion in 2023, KRW 18.2 billion in 2024, and KRW 14.6 billion in 2025, and in May 2024 it completed a small-scale merger with Fobaker Co., Ltd., launching an e-commerce business for online food distribution.
Clinical trials
data.go.kr9 MFDS clinical trial authorisations · 2016–2024 (Phase 1/2a 3 · Phase 1 3 · Phase 3 1 · Phase 1/2 1 · Phase 2b 1)
- Phase 1/2aBVAC-E6E72024-11-19
2 trial sites
- Phase 3AdCLD-CoV19-1 OMI2023-07-21
14 trial sites
- Phase 1/2AdCLD-CoV19-1 OMI2022-08-04
10 trial sites
- Phase 2bAdCLD-CoV19/ AdCLD-CoV19-12022-01-27
7 trial sites
- Phase 1AdCLD-CoV19/ AdCLD-CoV19-12021-07-23
7 trial sites
- Phase 1/2aAdCLD-CoV19/ AdCLD-CoV19-12020-12-04
7 trial sites
- Phase 1전립선특이적세포막항원과 전립선산탈인산화효소의 융합 암항원을 발현하도록 만들어진 PAPS 재조합유전자를 포함한 항암면역치료백신(BVAC-P)2020-03-24
- Phase 1인간상피성장인자수용체2를 재조합하여 만들어진 HER2K1117 재조합유전자를 포함한 항암면역치료백신(BVAC-B)2018-01-23
1 trial site
- Phase 1/2a인유두종바이러스 항원 재조합유전자를 포함한 세포기반 항암 면역치료백신(BVAC-C)2016-04-29
6 trial sites
R&D and key agreements
Source: DART corporate disclosureBVAC-C · 임상 2a상(면역관문억제제 병용임상 진행중) · Complete response observed in some patients; based on CeliVax platform
BVAC-E6E7 · 두경부암 · 임상 1/2a상(2024.11.19 IND 승인, 대상자 모집 시작) · Uses same cancer antigen as BVAC-C with an improved adenoviral vector
AdCLD-CoV19-1 · COVID-19 · 임상 1/2a상 완료 · Scalable manufacturing; safety and immunogenicity data secured
AdCLD-CoV19-1 OMI · 오미크론 변이 코로나19 · 임상 1/2상 완료, 임상 3상 진행(2023.07.21 식약처 승인) · All subjects dosed; data analysis underway
AdCLD-CoV19-1 LP.8.1 · LP.8.1 변이주 코로나19 · 개발중 · Targets the WHO/EMA/FDA-recommended 2025/26 variant strain
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition